
Bristol Myers Squibb offers growth and value in 2027, outperforming Novo Nordisk amid pricing pressures.
Bristol Myers Squibb (BMY) and Novo Nordisk (NVO) are healthcare leaders with different strengths: BMY in oncology and hematology, and NVO in obesity and diabetes treatments. BMY shows steady revenue and net income growth for 2027, with a low valuati...





